BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

Benzinga · 1d ago
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.